Hospital Pharmacy Segment generates 61.39% of Global Glioblastoma Multiforme Treatment Market Revenue

 GBM is the deadliest type of brain cancer, according to the National Foundation for Cancer Research, accounting for 45 percent of all malignant brain tumors. Furthermore, according to a study released by the National Brain Tumor Society, nearly 10% of persons with brain tumors are at high risk of acquiring glioblastomas. Glioblastoma is a type of brain tumor that develops from glioma, or supporting brain tissue. The aggressive malignant brain tumor, glioblastoma multiforme (abbreviated as GBM) has a terrible prognosis. The commercially accessible therapy option for this ailment confronts numerous hurdles, including drug concentration at the tumor site due to crossing the blood brain barrier. 

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market

Data Bridge Market Research analyses that the glioblastoma multiforme treatment market is expected to grow at a CAGR of 8.1% in the forecast period of 2022 to 2029 and is expected to reach USD 4,390.56 million by 2029. The rising prevalence of glioblastoma multiforme, more research and development, and favourable regulatory situations are all expected to drive market expansion. A strong pipeline is estimated to be a primary driver for the glioblastoma multiforme (GBM) therapy market during the forecast period. Also, the rising incidence of brain tumors is expected to enhance market growth.

Rising prevalence of glioblastoma multiforme is expected to drive the market's growth rate during the forecast period.

Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor, accounting for 77 percent to 81 percent of all primary malignant tumors in the central nervous system (CNS). According to the World Health Organization it's a grade IV diffuse astrocytic and oligodendroglial tumor. Primary GBM patients are on average 62 years old, with a median survival time of 14.6 months. The poor prognosis associated with GBM is widely recognized, and despite medicinal and surgical advancements, survival rates remain frustratingly low. According to the study, international research shows an annual incidence rate of 0.59 to 5 per 100,000 people; nonetheless, studies show an increase in incidence. In 2017, Miranda-Filho et al. reported rising CNS and brain malignancies rates in South America, Eastern Europe, and Southern Europe, with only Japan reporting declining rates. In two multicenter Australian investigations published in 2011, Dobes et al. found an increased incidence of GBM tumors, with a notable increase in frontal and temporal lobe GBM tumors. Glioblastoma multiforme is becoming more common, which increases the demand for early detection and diagnosis using cutting-edge technologies, boosting the global glioblastoma multiforme treatment market. Glioblastoma multiforme treatment is likely to become more popular as the global frequency of the disease rises.

Report Scope and Market Segmentation

Segment Analysis:

The glioblastoma multiforme treatment market is segmented on the basis of type, treatment, patient type, drug type, route of administration, end user and distribution channel.

• On the basis of type, the glioblastoma multiforme treatment market is segmented into primary (De Novo) and secondary. In 2022, the primary (De Novo) segment is expected to dominate the market with 89.67% market share owing to the high incidence of this type compared to the secondary, which makes it more common with a high rate of prevalence. 

In 2022, the primary (De Novo) segment is projected to hold the largest share of type segment in the glioblastoma multiforme treatment market

In 2022, the primary (De Novo) segment is anticipated to hold the largest share of global glioblastoma multiforme treatment market owing to the high incidence of this type as compared to the secondary which make it more common with high rate of prevalence. The primary (De Novo) segment is growing with a CAGR of 8.2% in the forecast period of 2022 to 2029.

• On the basis of treatment, the glioblastoma multiforme treatment market is segmented into surgery, radiotherapy and medications. In 2022, surgery segment is expected to dominate the market with 48.95% market share because this treatment is used to remove as much of the tumor as possible and is recommended as the first treatment option. 
• On the basis of patient type, the glioblastoma multiforme treatment market is segmented into adult, geriatric and child. In 2022, the adult segment is expected to dominate the market with 56.97% market share due to the high incidence of this among this patient pool. 
• On the basis of drug type, the glioblastoma multiforme treatment market is segmented into generics and branded. In 2022, the generics segment is expected to dominate the market with 68.81% market share owing to the low cost of the drug and ease of availability compared to branded drugs.

In 2022, the generics segment of drug type segment is anticipated to dominate the glioblastoma multiforme treatment market

In 2022, the generics segment of this market will dominate the glioblastoma multiforme treatment market owing to the low cost of the drug and ease of availability compared to branded drugs. The generics segment is expected reach the highest CAGR of 9.7% in the forecast period of 2022-2029. 

• On the basis of route of administration, the glioblastoma multiforme treatment market is segmented into parenteral, oral and others. In 2022, the parenteral segment is expected to dominate the market with 56.59% market share owing to the rapid absorption and faster onset of action of the drugs. Most of the drugs are available in this form. 
• On the basis of end user, the glioblastoma multiforme treatment market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the market with 58.24% market share as this segment specializes in conducting various surgical interventions and has a large professional's portfolio available for proper treatment.
• On the basis of distribution type, the glioblastoma multiforme treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2022, the hospital pharmacy segment is expected to dominate the market with 61.39% market share as healthcare organizations are the primary source of procurement of medication and therapies.

Major Players

Data Bridge Market Research recognizes the following companies as the major F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Zydus Cadila (India), Amneal Pharmaceuticals LLC. (U.S.), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Accord Healthcare (U.S.).

Market Development

• In April 2022, Elekta and GE Healthcare announced a global commercial collaboration agreement in radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. GE Healthcare and Elekta will continue to offer their own solutions based on standard interoperability, making it easier to connect to other vendors' systems. Since the arrangement is non-exclusive, each party is free to work with other partners. Both firms are eager to improve interoperability and streamline radiation oncology workflows.
• In December 2020, the United States Food and Drug Administration (FDA) had announced the approval for an investigational new drug application named berubicin for treating patients suffering from glioblastoma multiforme. In the first quarter of 2021, a trial examining the product's efficacy in adults with glioblastoma who have progressed on frontline treatment will begin. The trial has been modified based on contact between the regulatory agency and the pharmaceutical industry. Because the trial is adaptive, it allows for an interim analysis of the findings to show variations in efficacy between the approaches; it also allows for adjustments to the size of the study population for maximum efficacy over time.

Regional Analysis

Geographically, the countries covered in the Glioblastoma multiforme treatment market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.

As per Data Bridge Market Research analysis:

North America is the dominant region in Glioblastoma multiforme treatment market during the forecast period 2022 - 2029

North America will continue to dominate the Glioblastoma multiforme treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the easy accessibility of quality medical facilities and high awareness about rare disorders in this region. U.S. is estimated to dominate the North American region because of the increasing prevalence of the disease and favourable reimbursement policies.

Asia-Pacific is estimated to be the fastest growing region in Glioblastoma multiforme treatment market the forecast period 2022 - 2029

Asia-Pacific region is anticipated to grow at the highest rate during the forecast period of 2022-2029 due to the rising geriatric population, and growing investments in the healthcare sector in the region. Due to the surging number of research and development activities, Japan is anticipated to dominate the Asia-Pacific region.

COVID-19 Impact Analysis

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Over the last 18 months, almost every industry on the planet has suffered a setback. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The fast spread of COVID-19 around the globe had a significant influence on the treatment of recurrent glioblastoma multiforme and other malignancies. Radiotherapy, health monitoring and chemotherapy are not available to patients at health and surgery centers. The pandemic disrupted the worldwide pharmaceutical supply chain, making treatment for patients with recurrent glioblastoma multiforme more difficult to get. Over the forecast period, the aforementioned factors are likely to have a negative impact on the glioblastoma multiforme treatment market's revenue trajectory.

For more detailed information about the Glioblastoma multiforme treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market